Paul Nathan
保罗·内森
MBBS, PhD, FRCP
Consultant Medical Oncologist; Clinical Director, Cancer Services顾问肿瘤内科医师；癌症服务临床主任
👥Biography 个人简介
Paul Nathan, MBBS PhD FRCP is Consultant Medical Oncologist and Clinical Director of Cancer Services at Mount Vernon Cancer Centre, UK. He is a leading figure in British and European RCC clinical research, best known for his central role in COMPARZ, the phase III non-inferiority trial comparing pazopanib and sunitinib in advanced RCC. He leads multiple national and international IO combination trials and contributes to NICE and ESMO guideline development.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
COMPARZ: Pazopanib versus Sunitinib Non-Inferiority Trial
Co-led COMPARZ, the phase III trial demonstrating non-inferiority of pazopanib to sunitinib in progression-free survival in advanced clear-cell RCC, supporting pazopanib as an alternative first-line TKI and informing individualized treatment selection based on tolerability.
UK Immunotherapy Combination Trials in RCC
Led multiple UK-based phase I/II trials investigating novel immunotherapy combinations and sequencing strategies in advanced RCC, generating clinical data that informed international guideline recommendations and patient access programs.
NICE Technology Appraisals and RCC Guidelines
Served as clinical expert for UK National Institute for Health and Care Excellence (NICE) technology appraisals of multiple RCC agents, directly shaping national reimbursement decisions and standard-of-care recommendations in the United Kingdom.
Representative Works 代表性著作
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
New England Journal of Medicine (2013)
COMPARZ phase III non-inferiority trial demonstrating comparable efficacy of pazopanib and sunitinib in advanced RCC with differing tolerability profiles, enabling individualized TKI selection for patients.
Nivolumab plus Ipilimumab versus Sunitinib in First-Line Advanced Renal Cell Carcinoma: Extended Follow-Up in CheckMate 214
European Urology (2021)
Long-term follow-up analysis confirming durable OS benefit for nivolumab+ipilimumab, with contributions to UK site participation and collaborative interpretation of the data.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 保罗·内森 的研究动态
Follow Paul Nathan's research updates
留下邮箱，当我们发布与 Paul Nathan（Mount Vernon Cancer Centre）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment